IART

Over the past six months, Integra LifeSciences' stock has been impacted by several events. In July 2026, operational disruption from flooding in Cincinnati led to a cut in its 2026 outlook and preliminary third-quarter 2026 results, causing the stock to fall by 15.3%. The company has also been dealing with product recalls due to quality issues, which impacted earnings and share price, with news in September 2026 regarding $150 million in recalled products potentially returning, and remediation efforts for MediHoney® affecting Q4 2025 sales. In Q2 CY2026, Integra LifeSciences met Wall Street's revenue expectations with flat sales at $418.8 million but beat non-GAAP profit estimates by 15.8% with $0.56 per share. Q1 2026 showed signs of a potential turnaround with tissue reconstruction revenues growing 6.7% and wound reconstruction revenues growing 6.2% year-over-year due to improved supply chain, product quality, and strong demand, leading to a 33% EPS beat and a 46% year-to-date share price rebound. On October 9, 2026, the company priced $450 million in senior secured notes at 9.5% interest due in 2033 to refinance debt. As of October 9, 2026, analysts considered the stock potentially undervalued based on GF Value™, but also flagged it as a "possible value trap" due to unprofitability and negative cash flow.